Glycogen Synthase Kinase 3 Beta - Pipeline Review, H1 2020
Glycogen Synthase Kinase 3 Beta - Pipeline Review, H1 2020
SUMMARY
Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) – Glycogen synthase kinase 3 beta also known as GSK3B is an enzyme encoded by the GSK3B. It constitutively activate protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules. It mediates the development of insulin resistance by regulating activation of transcription factors. It regulates protein synthesis by controlling the activity of initiation factor 2B (EIF2BE/EIF2B5) in the same manner as glycogen synthase. It plays an important role in ERBB2-dependent stabilization of microtubules at the cell cortex. It phosphorylates MACF1, inhibiting its binding to microtubules which is critical for its role in bulge stem cell migration and skin wound repair. It regulates the circadian clock via phosphorylation of the major clock components including ARNTL/BMAL1, CLOCK and PER2.
Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) pipeline Target constitutes close to 18 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 8 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.
Report covers products from therapy areas Central Nervous System, Oncology, Musculoskeletal Disorders, Ophthalmology and Undisclosed which include indications Alzheimer's Disease, Pancreatic Cancer, Lung Cancer, Amyotrophic Lateral Sclerosis, Bladder Cancer, Bone Fracture, Breast Cancer, Cognitive Impairment, Glioblastoma Multiforme (GBM), Kidney Cancer (Renal Cell Cancer), Liver Cancer, Lymphoma, Metastatic Lung Cancer, Multiple Sclerosis, Myotonic Dystrophy, Neuroblastoma, Ovarian Cancer, Pervasive Developmental Disorder (PDD), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Primary Myelofibrosis, Retinitis Pigmentosa (Retinitis), Sarcomas, Tauopathies and Unspecified.
The latest report Glycogen Synthase Kinase 3 Beta – Pipeline Review, H1 2020, outlays comprehensive information on the Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) – Glycogen synthase kinase 3 beta also known as GSK3B is an enzyme encoded by the GSK3B. It constitutively activate protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules. It mediates the development of insulin resistance by regulating activation of transcription factors. It regulates protein synthesis by controlling the activity of initiation factor 2B (EIF2BE/EIF2B5) in the same manner as glycogen synthase. It plays an important role in ERBB2-dependent stabilization of microtubules at the cell cortex. It phosphorylates MACF1, inhibiting its binding to microtubules which is critical for its role in bulge stem cell migration and skin wound repair. It regulates the circadian clock via phosphorylation of the major clock components including ARNTL/BMAL1, CLOCK and PER2.
Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) pipeline Target constitutes close to 18 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 8 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.
Report covers products from therapy areas Central Nervous System, Oncology, Musculoskeletal Disorders, Ophthalmology and Undisclosed which include indications Alzheimer's Disease, Pancreatic Cancer, Lung Cancer, Amyotrophic Lateral Sclerosis, Bladder Cancer, Bone Fracture, Breast Cancer, Cognitive Impairment, Glioblastoma Multiforme (GBM), Kidney Cancer (Renal Cell Cancer), Liver Cancer, Lymphoma, Metastatic Lung Cancer, Multiple Sclerosis, Myotonic Dystrophy, Neuroblastoma, Ovarian Cancer, Pervasive Developmental Disorder (PDD), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Primary Myelofibrosis, Retinitis Pigmentosa (Retinitis), Sarcomas, Tauopathies and Unspecified.
The latest report Glycogen Synthase Kinase 3 Beta – Pipeline Review, H1 2020, outlays comprehensive information on the Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)
- The report reviews Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Overview
Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
Actuate Therapeutics Inc
Alzamend Neuro Inc
AMO Pharma Ltd
Angelini Group
Ankar Pharma SL
Avenzoar Pharmaceuticals Inc
CerebraMed
Collaborative Medicinal Development LLC
InnoBioscience LLC
Novosteo Inc
Park Active Molecules
Zovis Pharmaceuticals
Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Drug Profiles
9-ING41 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AL-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Dormant Products
Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Discontinued Products
Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Feb 11, 2020: Injectable drug for faster healing of bone fractures prepares for clinical trials
Sep 16, 2019: AMO Pharma participates in Workshop on central nervous system involvement in progression and treatment of Myotonic Dystrophy during Myotonic Dystrophy Foundation Annual Conference
Jun 13, 2019: Updates on development of AMO Pharma's AMO-02 presented at International Myotonic Dystrophy Consortium Meeting
May 06, 2019: AMO Pharma presents statistical analysis of results of phase 2 study of AMO-02 in adolescents with autism spectrum disorder
Dec 17, 2018: Actuate Therapeutics opens phase 1/2 clinical study of 9-ING-41 in patients with refractory cancers
Oct 30, 2018: AMO Pharma reports positive results from AMO-02 trial
Oct 23, 2018: AMO Therapeutics announces presentation of concordant analysis of results of phase 2 study of AMO-02 in treatment of myotonic dystrophy
Mar 15, 2018: AMO Pharma Announces Results of Phase 2 Proof-of-Concept Study of AMO-02 in Congenital and Childhood Onset Myotonic Dystrophy Type 1
Feb 15, 2018: Actuate Therapeutics Announces FDA Acceptance Of IND Application For 9-ING-41 And Clearance To Proceed With Clinical Study In Patients With Advanced Cancers
Oct 26, 2017: Actuate Therapeutics Receives Rare Pediatric Disease Designation for 9-ING-41 for Treatment of Neuroblastoma
Oct 18, 2017: AMO Pharma Presents Positive Interim Analysis of Data from Congenital Myotonic Dystrophy Study at American Neurological Association Annual Meeting
Sep 25, 2017: AMO Pharma Reports Update on Positive Interim Analysis for the First Cohort of Phase IIa Congenital Myotonic Dystrophy Study
Jul 27, 2017: AMO Pharma Receives FDA Orphan Drug Designation for AMO-02 for Treatment of Congenital Myotonic Dystrophy
May 30, 2017: AMO Pharma Announces FDA Fast Track Designation For AMO-02 For Treatment Of Congenital Myotonic Dystrophy
Apr 03, 2017: Actuate Therapeutics' Programs Highlighted in Clinical Cancer Research
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Overview
Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
Actuate Therapeutics Inc
Alzamend Neuro Inc
AMO Pharma Ltd
Angelini Group
Ankar Pharma SL
Avenzoar Pharmaceuticals Inc
CerebraMed
Collaborative Medicinal Development LLC
InnoBioscience LLC
Novosteo Inc
Park Active Molecules
Zovis Pharmaceuticals
Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Drug Profiles
9-ING41 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AL-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Dormant Products
Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Discontinued Products
Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Feb 11, 2020: Injectable drug for faster healing of bone fractures prepares for clinical trials
Sep 16, 2019: AMO Pharma participates in Workshop on central nervous system involvement in progression and treatment of Myotonic Dystrophy during Myotonic Dystrophy Foundation Annual Conference
Jun 13, 2019: Updates on development of AMO Pharma's AMO-02 presented at International Myotonic Dystrophy Consortium Meeting
May 06, 2019: AMO Pharma presents statistical analysis of results of phase 2 study of AMO-02 in adolescents with autism spectrum disorder
Dec 17, 2018: Actuate Therapeutics opens phase 1/2 clinical study of 9-ING-41 in patients with refractory cancers
Oct 30, 2018: AMO Pharma reports positive results from AMO-02 trial
Oct 23, 2018: AMO Therapeutics announces presentation of concordant analysis of results of phase 2 study of AMO-02 in treatment of myotonic dystrophy
Mar 15, 2018: AMO Pharma Announces Results of Phase 2 Proof-of-Concept Study of AMO-02 in Congenital and Childhood Onset Myotonic Dystrophy Type 1
Feb 15, 2018: Actuate Therapeutics Announces FDA Acceptance Of IND Application For 9-ING-41 And Clearance To Proceed With Clinical Study In Patients With Advanced Cancers
Oct 26, 2017: Actuate Therapeutics Receives Rare Pediatric Disease Designation for 9-ING-41 for Treatment of Neuroblastoma
Oct 18, 2017: AMO Pharma Presents Positive Interim Analysis of Data from Congenital Myotonic Dystrophy Study at American Neurological Association Annual Meeting
Sep 25, 2017: AMO Pharma Reports Update on Positive Interim Analysis for the First Cohort of Phase IIa Congenital Myotonic Dystrophy Study
Jul 27, 2017: AMO Pharma Receives FDA Orphan Drug Designation for AMO-02 for Treatment of Congenital Myotonic Dystrophy
May 30, 2017: AMO Pharma Announces FDA Fast Track Designation For AMO-02 For Treatment Of Congenital Myotonic Dystrophy
Apr 03, 2017: Actuate Therapeutics' Programs Highlighted in Clinical Cancer Research
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Actuate Therapeutics Inc, H1 2020
Pipeline by Alzamend Neuro Inc, H1 2020
Pipeline by AMO Pharma Ltd, H1 2020
Pipeline by Angelini Group, H1 2020
Pipeline by Ankar Pharma SL, H1 2020
Pipeline by Avenzoar Pharmaceuticals Inc, H1 2020
Pipeline by CerebraMed, H1 2020
Pipeline by Collaborative Medicinal Development LLC, H1 2020
Pipeline by InnoBioscience LLC, H1 2020
Pipeline by Novosteo Inc, H1 2020
Pipeline by Park Active Molecules, H1 2020
Pipeline by Zovis Pharmaceuticals, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Dormant Products, H1 2020 (Contd..2), H1 2020
Discontinued Products, H1 2020
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Actuate Therapeutics Inc, H1 2020
Pipeline by Alzamend Neuro Inc, H1 2020
Pipeline by AMO Pharma Ltd, H1 2020
Pipeline by Angelini Group, H1 2020
Pipeline by Ankar Pharma SL, H1 2020
Pipeline by Avenzoar Pharmaceuticals Inc, H1 2020
Pipeline by CerebraMed, H1 2020
Pipeline by Collaborative Medicinal Development LLC, H1 2020
Pipeline by InnoBioscience LLC, H1 2020
Pipeline by Novosteo Inc, H1 2020
Pipeline by Park Active Molecules, H1 2020
Pipeline by Zovis Pharmaceuticals, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Dormant Products, H1 2020 (Contd..2), H1 2020
Discontinued Products, H1 2020
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020
COMPANIES MENTIONED
Actuate Therapeutics Inc
Alzamend Neuro Inc
AMO Pharma Ltd
Angelini Group
Ankar Pharma SL
Avenzoar Pharmaceuticals Inc
CerebraMed
Collaborative Medicinal Development LLC
InnoBioscience LLC
Novosteo Inc
Park Active Molecules
Zovis Pharmaceuticals
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020
COMPANIES MENTIONED
Actuate Therapeutics Inc
Alzamend Neuro Inc
AMO Pharma Ltd
Angelini Group
Ankar Pharma SL
Avenzoar Pharmaceuticals Inc
CerebraMed
Collaborative Medicinal Development LLC
InnoBioscience LLC
Novosteo Inc
Park Active Molecules
Zovis Pharmaceuticals
